Recently we identi®ed FUS1 as a candidate tumor suppressor gene (TSG) in the 120 kb 3p21.3 critical region contained in nested lung and breast cancer homozygous deletions. Mutation of FUS1 is infrequent in lung cancers which we have con®rmed in 40 other primary lung cancers. In addition, we found no evidence for FUS1 promoter region methylation. Because haploinsuciency or low expression of Fus1 may play a role in lung tumorigenesis, we tested the eect of exogenously induced overexpression of Fus1 protein and found 60 ± 80% inhibition of colony formation for non-small cell lung cancer lines NCI-H1299 (showing allele loss for FUS1) and NCI-H322 (containing only a mutated FUS1 allele) in vitro. By contrast, a similar level of expression of a tumor-acquired mutant form of FUS1 protein did not signi®cantly suppress colony formation. Also, induced expression of Fus1 under the control of an Ecdysone regulated promoter decreased colony formation 75%, increased the doubling time twofold, and arrested H1299 cells in G1. In conclusion, our data are consistent with the hypothesis that FUS1 may function as a 3p21.3 TSG, warranting further studies of its function in the pathogenesis of human cancers. Oncogene (2001) 20, 6258 ± 6262.
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Keywords: tumor suppressor gene; growth inhibition; lung cancer Very frequent loss of one allele of chromosome arm 3p in both small lung cancer (SCLC) and non-small cell lung cancer (NSCLC) provides strong evidence for the existence of tumor suppressor genes (TSGs) in this chromosome region (Kok et al., 1987 (Kok et al., , 1997 Naylor et al., 1987; Whang-Peng et al., 1982; Wistuba et al., 2000) . Multiple dierent 3p regions showing isolated allele loss were identi®ed by detailed allelotyping studies suggesting there are several dierent TSGs located on 3p (Hibi et al., 1992; Killary et al., 1992; Wistuba et al., 2000) . We and others have found nested homozygous deletions in lung cancer and breast cancer cell lines at 3p21.3 that focused our search on a 630 kb region including the identi®cation, annotation, and evaluation of 25 new genes as TSG candidates (Daly et al., 1993; Kok et al., 1994; Lerman and Minna, 2000; Roche et al., 1996; Sekido et al., 1998; Wei et al., 1996) . A breast cancer deletion narrowed this region further to 120 kb and 9 TSG candidates (CACNA2D2, PL6, 106F6, NPRL2/g21, BLU, RASSF1, FUS1, HYAL2, HYAL1) were located in or bordering this region . One of these candidate TSGs, FUS1 (AF055479), did not show homology with any known genes, was found to have only few mutations in lung cancers, and was usually expressed at the mRNA level in lung cancers . Several NSCLCs (NCI-H322 and NCI-H1334) exhibited the same nonsense mutation, which arose from aberrant mRNA splicing. This aberrant form lacked 28 bp of mRNA at the 3' terminus of FUS1 exon 2 resulting in a truncated predicted protein of 82 amino acids compared to 110 amino acids in the wild-type (Figure 1 ). To con®rm our mutational analysis, which had previously been conducted on lung cancer cell line DNAs, we searched for other mutations in FUS1 in primary uncultured lung cancers. We performed single strand conformation polymorphism (SSCP) analysis using genomic DNA of 40 primary uncultured lung cancers (nine SCLCs and 31 NSCLCs) as previously described (Figure 1 legend) (Forgacs et al., 1998) . No mutations were detected although we found a single nucleotide polymorphism in intron 2 that did not alter the amino acid sequence of FUS1.
We next considered CpG island promoter region methylation as an epigenetic mechanism leading to TSG inactivation. We have extensive experience detecting such methylated promoter regions for other multiple genes in lung cancer . In fact, such tumor acquired promoter region methylation was found to occur for the RASSF1A mRNA isoform residing immediately centromeric to FUS1 (Burbee et al., 2001; Dammann et al., 2000) . However, FUS1 mRNA was expressed in most lung cancers making such CpG methylation an unlikely method of inactivation of FUS1 . In addition, we sequenced the 5' putative promoter region containing CpG islands of FUS1 using sodium bisul®te treated (Clark et al., 1994) DNA from six lung cancers where we did not detect FUS1 protein expression (see below) and found no CpG methylation.
We then considered the possibility of haploinsuciency or reduced expression of FUS1 as another mechanism for this gene to participate in lung cancer pathogenesis (Cook and McCaw, 2000; Di Cristofano et al., 1998; Xu et al., 2000) . We performed Western blot analysis of a panel of lung cancer cell lines using an anti-Fus1 anti peptide antibody which readily detected exogenously expressed Fus1 (Figure 2 ) but could not detect any endogenous FUS1 expression in lung cancers (Figure 2 for H1299 NSCLC given as an example of negative data). We realize this lack of detection could be due to a variety of factors including the quality of the anti-bodies and currently we are trying to produce other antisera. Nevertheless, if loss or low levels of FUS1 protein expression was involved in lung cancer pathogenesis we reasoned that exogenous introduction and expression of Fus1 might suppress the malignant phenotype. To study this we performed colony formation assays after transfection of FUS1 expression vectors. We made a C terminal FLAG-tagged FUS1 construct by PCR and ligated it into expression vector pcDNA3.1 (Invitrogen, Carlsbad CA, USA). Empty vector and an expression vector containing wild-type FUS1, FLAG-tagged FUS1, and the 82 aa mutant FUS1 were transfected into NSCLC NCI-H1299 cells which has suered allele loss for the 3p21.3 630 kb region and does not express detectable FUS1 protein (Figure 2 ), and NSCLC NCI-H322 cells containing a homozygous nonsense truncation mutation of FUS1 and also not expressing detectable FUS1 Three sets of primers were designed to cover the full FUS1 open reading frame for PCR ± SSCP analysis. The primers used were S1: GTTATGGTAGTGCGGACTG and AS1, GGTGGAACCATTGCCCTTAC; S2. GACCTGTGACATTTGCCGTG and AS2, CAACAGATCCCATCTGGGTC: S3; and CCTGAGCTGACCCCTTACA and AS3, TCTGTCTGCCACCTCCCAG protein (not shown). Expression of the FUS1 constructs in H1299 cells after transient transfection was con®rmed by Western blot analysis using anti-Flag and anti-N terminal FUS1 antibodies (Figure 2 ). We then tested the eect of FUS1 transfection with a neo resistance gene on lung cancer colony formation. The numbers of G418 resistant colonies in the FUS1 transfections were dramatically reduced in comparison with transfection with the empty vector (Figure 2) . By contrast, the number of colonies formed in the mutant FUS1 transfectants was only slightly reduced, suggesting that this lung cancer-associated mutant FUS1 was functionally inactive (Figure 2) .
We next developed an ecdysone inducible mammalian expression system in H1299 cells to con®rm that overexpression of FUS1 could inhibit tumor cell growth. In this system, FUS1 expression is induced in the presence of Ponasterone A. H1299 parent ECR9 cells with the regulatable hormone receptor vector pVgRXR alone served as an additional control. We ®rst transfected H1299 ECR9 cells with pINDsp1-FUS1-FLAG(neo), selected with G418 in the presence or absence of Ponasterone A, and compared the numbers of G418 resistant colonies. The number of colonies formed in cells with induced expression of FUS1 was decreased an average of 75+8% compared with the number of colonies in cells under uninduced conditions, con®rming the growth inhibitory activity of FUS1. Twenty stable G418 resistant clones were isolated in the uninduced condition and the inducible expression of FUS1-FLAG was examined. Among them, six clones showed some FUS1 induction and two stable clones were selected (Cl.13 and Cl.16) in which expression of FUS1-Flag was clearly inducible by Ponasterone A (Figure 3) . However, both cell lines expressed some FUS1 in the uninduced condition, indicating that regulation of FUS1 expression was leaky.
We examined the cell growth rate in induced and uninduced conditions by the MTT assay. Ponasterone A has no eect on the growth of parental H1299 ECR 9 cells, but the growth of Cl. 13 and Cl. 16 cells were inhibited in the presence of Ponasterone A (Figure 3) . The induction of Fus1 expression and inhibition of tumor cell growth appeared to be dependent on the dose of Ponasterone A both increasing with the increased concentrations of Ponasterone A (Figure 3) . With Fus1 induction, the doubling times of the tumor cells were also increased in both clones, from 22 to 46 h for Cl. 13 and from 21 to 45 h for Cl.16, respectively. These results indicated that overexpression Figure 2 (a) Western blot analysis of endogenous and transient expression of FUS1 in lung cancer cells. Transfection was performed according to the manufacturer's instruction using DMRIE C (Life Technologies, Inc., GIBCO BRL, Gaithersburg, MD, USA). NSCLC H1299 (2610 5 cells) were plated in 3.5 cm dishes 24 h before transfection and 2 mg of plasmid and 4 ml of DMRIE C were used for each transfection. All of the plasmids were resequenced after PCR construction and the sequences of the various FUS1 open reading frames were veri®ed. Ten ml of lysate was made from 2610 4 cells using sample buer (100 mM Tris 2% SDS 10% b-mercaptoethanol 20% glycerol 0.03% PBP) and run in 12.5% SDS ± PAGE gels followed by transfer to nitrocellulose membranes. After blocking with 5% dry milk and 0.2% Tween 20 in PBS, the membranes were incubated at room temperature for 1 h with rabbit polyclonal antibodies. Anti FUS1 antibodies (1 : 300 dilution of sera) were generated by immunizing rabbits (Strategic Biosolution, Ramona, CA, USA) with peptides corresponding to amino acid 1 to 15 of the human FUS1 protein sequence. Anti-FLAG antibody M2 was from Sigma (St. Louis, MO, USA). The membranes were developed after incubation in the presence of peroxidase-labeled anti-rabbit or anti-mouse IgG antibodies using Super Signal chemiluminescent substrate (Pierce Rockford, IL, USA). The calculated molecular weight of FLAGtagged FUS1 is 15 kd and the size of the band that was recognized by both antibodies is slightly higher than the calculated size. As expected the mutant FUS1 (predicted to be 82 amino acids) is slightly smaller than wild type FUS1 (110 amino acids). (b) Results of colony formation assays in H1299 NSCLC cells. After transfection, the H1299 cells were trypsinized, replated and cultured in G418 (600 mg/ml) supplemented medium (RPMI 1640 5% fetal bovine serum) for 2 or 3 weeks and the number of G418 resistant colonies counted after staining with methylene blue in ethanol/PBS (50/50%). Note dramatic suppression of colony formation after transfection with FUS1 and FUS1-FLAG but much less suppression with the 82 amino acid aberrant FUS1 construct. The mean and standard deviations for an average of 2 ± 4 plates for two or more experiments for H1299
were: vector control pcDNA3.1, 100+18% (100%=248 colonies), FUS1-FLAG 16+10%, FUS1 23+11%, FUS1 mutant 77+11%. Colony numbers of FUS1 and FUS1-FLAG transfected cells were signi®cantly reduced (P50.01, Student's t-test) compared with vector control. H322 cells had 40+34% colony formation with FUS1-FLAG transfection compared to 100% for vector control (P50.05) Figure 3 for details) we found: parental H1299-ECR9 cells to have unchanged cell cycle parameters (G1 51%, S 18%, G2/M 31% uninduced and G1 50%, S 18%, G2/M 32% induced); while Fus1 induced clones showed G1 arrest (H1299 clone13 showed G1 50%, S 17%, G2/M 33% uninduced and G1 65%, S 10%, G2/M 25% induced; and H1299 clone16 G1 56%, S 16%, G2/M 28% uninduced and G1 65%, S 12%, G2/M 23% induced). The increase in G1% was signi®cant (P50.05, Student's t-test). These results suggest that overexpression of FUS1 in H1299 cells is associated with G1 arrest and alteration of cell cycle kinetics.
In this study, we demonstrate that lung cancer cell lines do not express detectable endogenous levels of Fus1 protein, and that exogenous introduction of Fus1 with overexpression inhibited lung cancer cell growth in vitro. This growth inhibition was seen in a lung cancer line suering allele loss for the region and in another carrying a homozygous truncating mutation of FUS1. In addition, we found that this truncated Fus1 protein had lost tumor growth suppressing activity. Besides the acute transfection studies, we established a Fus1 inducible system and showed that tumor growth inhibition was correlated with the level of expression of Fus1 protein. In addition, cell cycle analysis using the same expression-regulatable system showed that the mechanism for the inhibition of cell growth was associated with G1 arrest and not with induction of apoptosis. Finally, we con®rmed that somatic mutation of FUS1 was rare in primary lung cancers (0/40), in agreement with previous studies which showed 3/79 lung cancers with alterations in the FUS1 gene (two nonsense mutations and one deletion). In fact the frequency of mutation in any of the 22 out of 25 candidate genes we have studied in detail in this 600 kb 3p21.3 region is low compared to the high frequency LOH at this locus. One possibility to account for the Figure 3 (a) Induction of FUS1 protein by Ecdysone expression vector (Invitrogen, Carlsbad, CA, USA) under the control of the Ponasterone A in NCI-H1299 stable transfected clones. We transfected the regulatable hormone receptor vector pVgRXR into H1299 and obtained 20 Zeocin (selection marker of pVgRXR) resistant clones. These stable pVgRXR transfectants were screened for b-gal activity following transfection with pINDLacZ. From these clones we selected clone ECR 9 as a parent cell line in which b-gal activity was speci®cally regulated by Ponasterone A in H1299 cells. We made an expression vector which contained FUS1-FLAG (pIND sp1-FUS1-FLAG) and transfected this into ECR 9. Western analysis. Ten mg total cell lysate protein from each cell line and anti-FUS1 antibody were used for the analysis. The concentration (mM) of Ponasterone A used for induction is indicated above the blots. ECR9 is H1299 parent cell line transfected with the regulatory vector alone; clones 13 and 16 represent H1299 clones containing a regulatable FUS1 vector. The in vitro growth of (b) NSCLC H1299ECR 9 (control), (c) H1299FUS1Clone13 and (d) H1299FUS1Clone16 was measured by the MTT assay. Cells (10 4 ) were plated in 1 ml of RPMI 1640 (Life Technologies Inc.) with 5% fetal bovine serum and cultured in the presence (1, 5 mM) or absence of Ponasterone A in a 24 well plate (added at day 0) and wells were harvested for MTT assays at the days indicated. MTT (Sigma) was added to the cultures (500 mg/ml), incubated at 378C for 2 h, the intracellular formazan crystals solubilized with isopropanol containing 0.01 N HCl, and the absorbance of the solution at 560 nm was measured using a spectrophotometer. The OD 560 is directly proportioned to cell number in the range of 0 ± 1.2. Data points represent an average of three wells with SD (contained within the symbols) of each data point *5%. For cell cycle distribution analysis of the FUS1 inducible H1299 clones, cells (2610 5 ) of ERC 9, CL.13 and Cl.16 were plated on 10 cm dishes and cultured in the presence (5 mM) or absence of Ponasterone A for 2 days. Cells were harvested, ®xed in 50% ethanol/PBS, treated with 5 mg/ml RNase, stained with propidium iodide and analysed for DNA content by FACSCaliber instrument (Becton Dickinson, San Jose, CA, USA). FACS analysis was performed in three independent experiments with similar results. Under FUS1 induced conditions the per cent of cells in G1 increases signi®cantly (P50.05) compared to controls low mutation frequency is loss of expression of FUS1 or another of the 3p21.3 genes by tumor promoter acquired methylation. In this regard, we and another group found that the expression of RASSF1A mRNA isoform isolated from the same 3p21.3 deletion region and 15.5 kb centromeric of FUS1 was repressed in many lung cancers by acquired CpG island promoter DNA methylation for this gene (Burbee et al., 2001; Dammann et al., 2000) . However we have not found loss of FUS1 mRNA expression or 5' region CpG methylation for FUS1 in lung cancers (this report) thus excluding tumor-acquired promoter methylation as an inactivating mechanism for the FUS1 gene. It is possible that some mechanisms such as post transcriptional or post translational modi®cation may prevent the functional expression of Fus1 protein, for example, by altering protein or mRNA half life. Another possibility is that FUS1 acts as a haploinsucient tumor suppressor gene (Cook and McCaw, 2000) . Our experiments showed that overexpression of FUS1 caused G1 arrest in H1299. Although some signal or environmental cue may induce the expression of Fus1 and lead to G1 arrest in normal cells, 3p allelic loss and some other alteration of FUS1 in malignant cells may lead to haploinsuciency and/or loss of expression of FUS1 in lung tumors and escape from cell cycle arrest. This work should lead to further studies examining the role of FUS1 in the pathogenesis of lung and other cancers.
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